GuidelineJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2024
S2k guideline basal cell carcinoma of the skin (update 2023).
Guideline in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- S2k guideline basal cell carcinoma of the skin (update 2023).Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2024Guideline
- Review
- Expert opinion: radiotherapy for basal cell carcinoma : Recommendations from the DEGRO Dermatooncology Working Group.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- From Ultrasound to Histopathology: Agreement Analysis and Depth Correction Model for Basal Cell Carcinoma Using a Portable 20 MHz High-Frequency Ultrasound Device.Diagnostics (Basel, Switzerland) · 2026Article
- Laser Therapy in Basal Cell Carcinoma: Current Evidence, Literature Gaps and Future Perspectives.Bioengineering (Basel, Switzerland) · 2026Review
- Clinical distribution patterns and histopathological features of 2016 cases of basal cell carcinoma: a retrospective study from Southwest China.European journal of medical research · 2026Article
- Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies.Frontiers in physiology · 2026Review
- Microscopically controlled two-step surgery for head and neck non-melanoma skin cancer: the role of primary resection and planned secondary wound closure.Frontiers in oncology · 2026Article
- [New systemic treatment approaches for malignant eyelid tumors].Die Ophthalmologie · 2025Review
- Comparison of clinical effects and patient satisfaction between ultra-pulsed CO₂ laser treatment and surgical excision in patients with facial basal cell carcinoma.Frontiers in surgery · 2025Article
- X-Ray Therapy of Skin Cancer at Critical Facial Sites: Results of a Tertiary Referral Center.Dermatology (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basal cell carcinoma is the most common malignant tumor in the fair-skinned population and its incidence continues to rise. An update of the S2k guideline with the participation of all specialist societies familiar with the clinical picture and previous literature research is of great importance for the quality of care for affected patients. In addition to epidemiology, diagnostics and histology are discussed. After risk stratification, therapy is divided into topical, systemic and radiation therapy. Surgical removal remains the treatment of first choice in most cases. The approval of anti-PD1 inhibitors for locally advanced and metastatic tumors has opened up a new option in second-line therapy (after hedgehog inhibitors).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.